
Affimed prices public offering to finance NK cell trials
German Affimed N.V. has priced its previously announced public offering of 22,500,000 common shares at a $4.00 per common share. A 30-day...

Four new autoantigens trigger multiple sclerosis
Despite considerable progress in the treatment of multiplesclerosis (MS), the disease still often leads to permanent neurological disability....

Bayer invests into synthetic TCRs for cell therapy
Sometimes it's not bad to have old contacts like Jak Knowles, CEO of Boston-based Affini-T Therapeutics Inc., which left stealth mode at the J.P....

Evotec signs contracts with Almirall and Sernova
Under the alliance Evotec is set to discover novel targets or therapeutics for skin diseases such as atopic dermatitis or basal cell carcinoma....

Novo Holdings co-leads €40m Qure.ai financing
Qure.ai said it will use the proceeds from the $40m financing round to intesify product development for critical care and community...

G7 heads call for decarbonisation of industry
The G7 ministers underlined the importance of efforts to improve energy efficiency, the need for increased investment in renewable energy, tracking...

Scientists print 3D cancer model
Using a bio-ink made from alginate and human cells, researchers at the Technical University of Berlin have 3D printed a model of a cancer metastasis...